Who
Ezio Bonvini
Sr VP, Research & CSO
Company insider
Files Form 4 as: Sr VP, Research & CSO, MacroGenics.
In numbers
- Trades disclosed
- 145
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $5.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Oct 2013
- Last trade
- 6 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Oct 2026filed 7 Oct 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | $21K8,000 at $2.60 | filing |
| 6 Oct 2026filed 7 Oct 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | $21K8,000 at $2.60 | filing |
| 17 Aug 2026filed 18 Aug 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | $104K40,000 at $2.60 | filing |
| 17 Aug 2026filed 18 Aug 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | $104K40,000 at $2.60 | filing |
| 17 Aug 2026filed 18 Aug 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | $104K40,000 at $2.60 | filing |
| 17 Aug 2026filed 18 Aug 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | $104K40,000 at $2.60 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —16,665 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $11K6,433 at $1.71 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,665 at $0.00 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,665 at $0.00 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —16,665 | filing |
| 15 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $11K6,433 at $1.71 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —187,500 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,250 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —187,500 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code M | —11,166 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,166 at $0.00 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsBiotechnology | SEC FORM 4 Code F | $7,8034,311 at $1.81 | filing |
| 8 Feb 2026filed 10 Feb 2026 | MGNX MacroGenicsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,166 at $0.00 | filing |
News
MacroGenics Announces First Patient Dosed in Phase 1 Study of MGC030 in Patients with Advanced Solid TumorsMGNX · manilatimes.net · 15 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)MGNX · themarketsdaily.com · 14 Oct 2026MacroGenics (NASDAQ:MGNX) vs. Keros Therapeutics (NASDAQ:KROS) Head to Head ReviewMGNX · tickerreport.com · 7 Oct 2026
0 headlines in the last 90 days name Ezio Bonvini; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.